TD Cowen initiated coverage of C4 Therapeutics (CCCC) with a Buy rating and no price target C4 is one of the few companies with clinical validation across molecular glues and heterobifunctional degraders, the analyst tells investors in a research note. The firm believes the company’s Cemsi could become a “backbone therapy” for myeloma .
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CCCC: